> ## Content Index > Fetch the complete content index at: https://www.bullished.co/llms.txt > Use this file to discover other available public pages before exploring further. # AbCellera Narrows Loss To $40.8 Million From $57.1 Million As Research Spending Falls - URL: https://www.bullished.co/abcellera-narrows-loss-to-40-8-million-from-57-1-million-as-research-spending-falls-6d5c7d07/ - Published: 2026-11-09T21:35:48.000Z - Updated: 2026-11-09T21:35:48.000Z - Description: The antibody developer currently plans to stop ABCL575 after early-stage testing, even though the study met its goals. - Author: Matteo Parrino - Tags: SEC Filings, ABCL, Industry: Healthcare AbCellera Biologics, which develops antibody medicines for its own pipeline and drug-company partners, narrowed its third-quarter loss to [$40.8 million](https://www.businesswire.com/news/home/20261109441631/en/AbCellera-Reports-Q3-2026-Business-Results?ref=bullished.co) from $57.1 million a year earlier as research and administrative spending fell, according to its earnings release furnished with an SEC filing Monday. The company also said it currently plans no further development of its experimental skin-disease treatment ABCL575 beyond early-stage testing, although the trial met its goals. ## Lower Spending, Mixed Revenue AbCellera's unaudited results put the basic and diluted loss per share at $0.13, versus $0.19 a year earlier. Third-quarter revenue [rose to $10.6 million](https://www.sec.gov/Archives/edgar/data/0001703057/000170305726000058/q32026earningspressrelease.htm?ref=bullished.co) from $9.0 million, with research fees supplying nearly all of the latest quarter's sales. Research expenses were [$43.5 million](https://www.businesswire.com/news/home/20261109441631/en/AbCellera-Reports-Q3-2026-Business-Results?ref=bullished.co), down from $55.0 million. Selling and administrative costs fell to $13.6 million from $25.0 million, while the operating loss narrowed to $53.3 million from $76.3 million. The quarter's improvement did not extend to the full year-to-date picture. For the first nine months, revenue fell to $23.0 million from $30.3 million as licensing and royalty revenue declined to $431,000 from $10.8 million. The nine-month net loss widened to $139.4 million from $137.5 million. Operating cash flow moved in the opposite direction: AbCellera generated $19.313 million during the first nine months, versus using $96.552 million a year earlier. The cash-flow statement included a $66.1 million increase in deferred revenue. ## ABCL575 Stops At Early Testing ABCL575 targets atopic dermatitis, a skin condition, and other autoimmune diseases. Its [early-stage study met](https://www.sec.gov/Archives/edgar/data/0001703057/000170305726000058/q32026earningspressrelease.htm?ref=bullished.co) all goals, and the company reported favorable tolerability and drug exposure that could support longer intervals between doses. AbCellera nevertheless currently does not plan to advance it further. The trial involved 40 healthy participants, with 30 receiving ABCL575 and 10 receiving placebo. The company reported no serious adverse events and estimated the drug's mean half-life—the time for its concentration to fall by half—at approximately 65 days in its [business presentation](https://www.sec.gov/Archives/edgar/data/0001703057/000170305726000058/a2026q3businessupdatenov.htm?ref=bullished.co). Other candidates moved into preparations for human testing. ABCL992 is a version of the hot-flash candidate ABCL635 designed for less frequent dosing; ABCL385 is an oncology candidate; and ABCL646 targets an ion channel. Work also continued on ABCL386 and ABCL688. Alongside its internal drugs, AbCellera earns partnership research and access fees, intellectual-property payments, development milestones and royalties. At quarter-end, it believed 34 partner-led programs with potential future financial returns were progressing, down from 44 at the end of 2025\. It also retained financial stakes in 12 clinical-stage molecules understood to be progressing. ## Hot-Flash Data Fund The Next Push AbCellera announced [positive mid-stage results](https://www.sec.gov/Archives/edgar/data/0001703057/000170305726000053/abcl-20260810.htm?ref=bullished.co) for ABCL635 on August 10 and priced its public offering on August 12\. Monday's update confirmed completion of the $200 million offering of common shares and pre-funded warrants. “On the strength of this data, we raised $200 million,” founder and CEO Carl Hansen said in the [earnings release](https://www.sec.gov/Archives/edgar/data/0001703057/000170305726000058/q32026earningspressrelease.htm?ref=bullished.co). Quarter-end available liquidity [exceeded $890 million](https://www.sec.gov/Archives/edgar/data/0001703057/000170305726000058/a2026q3businessupdatenov.htm?ref=bullished.co), including more than $790 million in cash balances and marketable securities and over $100 million in government funding that does not require issuing shares. AbCellera expects to begin late-stage development for menopause-related hot flashes in 2027\. It also expects trials in 2027 for hot flashes caused by hormone-suppression treatments for breast and prostate cancer. AbCellera anticipates releasing ABCL635's 12-week results and extension-study data in early 2027. Learn - [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations) From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples ### Sources - [8-K Filing — AbCellera Biologics Inc. (ABCL)](https://www.sec.gov/Archives/edgar/data/0001703057/000170305726000058/abcl-20261109.htm?ref=bullished.co) — SEC EDGAR - [Exhibit q32026earningspressrelease.htm — AbCellera Biologics Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001703057/000170305726000058/q32026earningspressrelease.htm?ref=bullished.co) — SEC EDGAR - [Exhibit a2026q3businessupdatenov.htm — AbCellera Biologics Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001703057/000170305726000058/a2026q3businessupdatenov.htm?ref=bullished.co) — SEC EDGAR - [AbCellera Reports Q3 2026 Business Results](https://www.businesswire.com/news/home/20261109441631/en/AbCellera-Reports-Q3-2026-Business-Results?ref=bullished.co) — businesswire.com - [8-K filed 2026-08-10 — AbCellera Biologics Inc. (earlier disclosure)](https://www.sec.gov/Archives/edgar/data/0001703057/000170305726000053/abcl-20260810.htm?ref=bullished.co) — SEC EDGAR